We recently published 10 Stocks Jim Cramer Talked About. Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer talked ...

Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings ...

Pfizer has outperformed the S&P 500 since my previous call, driven by improving fundamentals and renewed share price momentum ...

Pfizer is penning a cancer discovery pact with Cartography Biosciences that could max out at $865 million biobucks. | Pfizer ...

Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

Pfizer recently announced its guidance for 2026. One thing seems clear: Its financial results won't get much stronger. It ...

Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched ...

Albert Bourla said Pfizer has discussed a fast-pass voucher with the White House during the JPMorgan Healthcare Conference.

Pfizer is gearing up for a consumer-driven obesity drug market, drawing parallels to the demand surge it experienced with the ...

However, there's one potentially lucrative growth opportunity that Pfizer's focusing on that could change things and ...

In the latest close session, Pfizer (PFE) was up +1.63% at $25.56. This move outpaced the S&P 500's daily loss of 0.53%. On the other hand, the Dow registered a loss of 0.09%, and the ...

The partnership brings together Pfizer’s scientific data and therapeutic expertise with Boltz’s open-source AI foundation ...